| Author/Editor | Decramer, Marc; Celli, Bartolome; Kesten, Steven; Lystig, Theodore; Mehra, Sunil; Tashkin, Donald P; Šuškovič, S; Košnik, M; Turel, M; Rezar, I; Ulčar-Kostič, S | |
| Title | Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial | |
| Type | članek | |
| Source | Lancet | |
| Vol. and No. | Letnik 374, št. 9696 | |
| Publication year | 2009 | |
| Volume | str. 1171-8 | |
| Language | eng | |
| Abstract | Background: The beneficial effects of pharmacotherapy for chronic obstructive pulmonary disease (COPD) are well established. However, there are few data for treatment in the early stages of the disease. We examined the effect of tiotropium on outcomes in a large subgroup of patients with moderate COPD. Methods: The Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) study was a randomised, double-blind, placebo-controlled trial undertaken in 487 centres in 37 countries. 5993 patients aged 40 years or more with COPD were randomly assigned to receive 4 years of treatment with either once daily tiotropium (18 microg; n=2987) or matching placebo (n=3006), delivered by an inhalation device. Randomisation was by computer-generated blocks of four, with stratification according to study site. In a prespecified subgroup analysis, we investigated the effects of tiotropium in patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II disease. Primary endpoints were the yearly rates of decline in prebronchodilator forced expiratory volume in 1 s (FEV(1)) and in postbronchodilator FEV(1), beginning on day 30 until completion of double-blind treatment. The analysis included all patients who had at least three measurements of pulmonary function. This study is registered with ClinicalTrials.gov, number NCT00144339. Findings: 2739 participants (mean age 64 years [SD 9]) had GOLD stage II disease at randomisation (tiotropium, n=1384; control, n=1355), with a mean postbronchodilator FEV(1) of 1.63 L (SD 0.37; 59% of predicted value). 1218 patients in the tiotropium group and 1157 in the control group had three or more measurements of postbronchodilator pulmonary function after day 30 and were included in the analysis. The rate of decline of mean postbronchodilator FEV(1) was lower in the tiotropium group than in the control group (43 mL per year [SE 2] vs 49 mL per year [SE 2], p=0.024). (Abstract truncated at 2000 characters) | |
| Descriptors | SEVERITY OF ILLNESS INDEX AGED BRONCHODILATOR AGENTS DISEASE PROGRESSION DOUBLE-BLIND METHOD FORCED EXPIRATORY VOLUME HEALTH STATUS LINEAR MODELS PATIENT ADMISSION PROPORTIONAL HAZARDS MODELS QUALITY OF LIFE QUESTIONNAIRES SCOPOLAMINE DERIVATIVES TREATMENT OUTCOME |